Trial intelligence / Profile preview

DE-101 (Rivoglitazone) in Dry Eye Disease

NCT01118754Phase 2Completed

Sponsor
Santen Pharmaceutical
Start
Apr 2010
Primary completion
Dec 2010
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of rivoglitazone in dry eye disease (DED), sponsored by Santen Pharmaceutical. Started Apr 2010; status: completed.

02

Drugs

rivoglitazone
03

Conditions

dry eye disease (DED)

Beyond the preview

Go deeper on NCT01118754.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01118754.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call